Atezolizumab + Cabozantinib
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell
Trial Timeline
Jul 28, 2020 → Mar 24, 2025
NCT ID
NCT04338269About Atezolizumab + Cabozantinib
Atezolizumab + Cabozantinib is a phase 3 stage product being developed by Chugai Pharmaceutical for Carcinoma, Renal Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT04338269. Target conditions include Carcinoma, Renal Cell.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04338269 | Phase 3 | Terminated |
Competing Products
20 competing products in Carcinoma, Renal Cell